Azenta, Inc. (NASDAQ:AZTA – Get Free Report) has earned an average recommendation of “Hold” from the seven brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $36.20.
A number of research analysts have issued reports on AZTA shares. Evercore ISI set a $33.00 target price on shares of Azenta and gave the company an “in-line” rating in a research report on Tuesday, August 5th. Jefferies Financial Group upgraded shares of Azenta from a “hold” rating to a “buy” rating and upped their target price for the company from $30.00 to $38.00 in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Azenta in a research report on Wednesday, October 8th. Stephens started coverage on shares of Azenta in a research report on Tuesday, July 22nd. They set an “equal weight” rating and a $35.00 target price on the stock. Finally, Raymond James Financial upgraded shares of Azenta from a “market perform” rating to an “outperform” rating and set a $35.00 target price on the stock in a research report on Wednesday, August 6th.
Read Our Latest Stock Analysis on AZTA
Institutional Trading of Azenta
Azenta Trading Up 1.8%
Azenta stock opened at $30.73 on Tuesday. Azenta has a 1 year low of $23.91 and a 1 year high of $55.63. The company has a market cap of $1.41 billion, a PE ratio of -12.70 and a beta of 1.62. The company’s 50-day moving average is $30.60 and its two-hundred day moving average is $29.93.
Azenta (NASDAQ:AZTA – Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. Azenta had a negative net margin of 18.45% and a positive return on equity of 1.35%. The company had revenue of $143.94 million for the quarter, compared to the consensus estimate of $149.64 million. During the same period in the prior year, the company posted $0.14 EPS. The company’s revenue was up .0% compared to the same quarter last year. Research analysts forecast that Azenta will post 0.53 EPS for the current year.
Azenta Company Profile
Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
Featured Stories
- Five stocks we like better than Azenta
- What Are Dividend Champions? How to Invest in the Champions
- Semiconductor Supercycle: Why Onsemi Stock Could Double as AI and EV Growth Accelerate
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- The Best Local Butchers for Thanksgiving [2025 Survey]
- How to Calculate Options Profits
- $134M in Insider Moves: What It Might Mean for KMI, ISRG and QS
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
